Previous studies have not reported any major adverse safety signals associated with the mothers exposure to interferon beta or glatiramer acetate on risk of obstetric/neonatal complications and congenital malformations [3-5], although some studies have suggested potential harm of interferon beta in terms of lower mean birth weight and length and preterm birth [2]. This evidence concerns the gene IFNB1 and pregnancy disorder.